NZ331614A - 2-arylpyrazolisoquinoline and cinnolinone derivatives to treat asthma and/or rhinitis - Google Patents

2-arylpyrazolisoquinoline and cinnolinone derivatives to treat asthma and/or rhinitis

Info

Publication number
NZ331614A
NZ331614A NZ331614A NZ33161497A NZ331614A NZ 331614 A NZ331614 A NZ 331614A NZ 331614 A NZ331614 A NZ 331614A NZ 33161497 A NZ33161497 A NZ 33161497A NZ 331614 A NZ331614 A NZ 331614A
Authority
NZ
New Zealand
Prior art keywords
arylpyrazolisoquinoline
cinnolinone
rhinitis
derivatives
treat asthma
Prior art date
Application number
NZ331614A
Inventor
John Bantick
Roger Bonnert
Peter Cage
David Donald
Mark Furber
Simon Hirst
Matthew Perry
Eifion Phillips
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605803.7A external-priority patent/GB9605803D0/en
Priority claimed from GBGB9610474.0A external-priority patent/GB9610474D0/en
Priority claimed from GBGB9610894.9A external-priority patent/GB9610894D0/en
Priority claimed from GBGB9700862.7A external-priority patent/GB9700862D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of NZ331614A publication Critical patent/NZ331614A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The specification describes 2-arylpyrazolisoquinoline and cinnolinone derivatives and their use in the treatment of asthma and rhinitis. Variables of most interest are where: X is C=O, C=S, C=NR15, CR3R6 or NR4; R15 is C1-C6 or H; R3 is H or a bond R6 is C1-C6 or H Y is N or NR7 or CR18, R7 is C1-C6 or H R18 is C1-C6 or H and Z is OR8 or O R8 is C1-C6 or H.
NZ331614A 1996-03-20 1997-03-20 2-arylpyrazolisoquinoline and cinnolinone derivatives to treat asthma and/or rhinitis NZ331614A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9605803.7A GB9605803D0 (en) 1996-03-20 1996-03-20 Pharmaceutically-active compound
GBGB9610474.0A GB9610474D0 (en) 1996-05-18 1996-05-18 Pharmaceutically active compounds
GBGB9610894.9A GB9610894D0 (en) 1996-05-24 1996-05-24 Pharmaceutically useful compounds
GBGB9700862.7A GB9700862D0 (en) 1997-01-16 1997-01-16 Pharmaceutically useful compounds
PCT/SE1997/000471 WO1997034893A1 (en) 1996-03-20 1997-03-20 Pharmaceutically useful compounds

Publications (1)

Publication Number Publication Date
NZ331614A true NZ331614A (en) 2000-07-28

Family

ID=27451427

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ331614A NZ331614A (en) 1996-03-20 1997-03-20 2-arylpyrazolisoquinoline and cinnolinone derivatives to treat asthma and/or rhinitis

Country Status (19)

Country Link
EP (1) EP0888347A1 (en)
JP (1) JP2000506884A (en)
KR (1) KR20000064716A (en)
CN (1) CN1218472A (en)
AR (1) AR006520A1 (en)
AU (1) AU712141B2 (en)
BR (1) BR9708103A (en)
CA (1) CA2247814A1 (en)
CZ (1) CZ297798A3 (en)
EE (1) EE9800298A (en)
ID (1) ID16283A (en)
IL (1) IL126271A0 (en)
IS (1) IS4848A (en)
NO (1) NO984290L (en)
NZ (1) NZ331614A (en)
PL (1) PL328921A1 (en)
SK (1) SK118798A3 (en)
TR (1) TR199801861T2 (en)
WO (1) WO1997034893A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110749A1 (en) * 2001-03-07 2002-09-12 Bayer Ag Substituted aminodicarboxylic acid derivatives
JP2003002863A (en) * 2001-06-25 2003-01-08 Nippon Soda Co Ltd Method for producing benzoic acids, and new compound
SE0102404D0 (en) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
US6642249B2 (en) 2001-07-04 2003-11-04 Active Biotech Ab Immunomodulating compounds
DE10229762A1 (en) * 2002-07-03 2004-01-22 Aventis Pharma Deutschland Gmbh Pyrazoloisoquinoline derivatives for the inhibition of NFkappaB-inducing kinase
JP2006509047A (en) * 2002-11-22 2006-03-16 アクティブ バイオテック アクチボラーグ Pyrazoloquinolines with immunomodulatory activity
ATE425164T1 (en) 2002-12-16 2009-03-15 Active Biotech Ab TETRACYCLIC IMMUNOMODULATING COMPOUNDS
BRPI0408365B8 (en) * 2003-03-14 2021-05-25 Avidex Ltd heterocyclic immunomodulating compounds
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
PA8619901A1 (en) 2003-12-12 2005-11-25 Wyeth Corp USEFUL KINOLINES IN THE TREATMENT OF CARDIOVASCULAR DISEASES
FR2870239B1 (en) * 2004-05-11 2006-06-16 Sanofi Synthelabo DERIVATIVES OF 2H- OR 3H-BENZO [E] INDAZOL-1-YLE CARBAMATE, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
AU2004322237B2 (en) 2004-08-09 2011-09-22 Medigene Ag Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors
AP2527A (en) 2006-10-31 2012-12-06 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptorantagonists
CN102372710A (en) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 Fused cyclic compound being taken as mineral corticoid recept antagonist
JPWO2012108511A1 (en) 2011-02-09 2014-07-03 日産化学工業株式会社 Pyrazole derivatives and pest control agents
US20210355123A1 (en) * 2018-09-07 2021-11-18 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
TW202337453A (en) 2022-03-17 2023-10-01 美商英塞特公司 Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524146A (en) * 1982-12-08 1985-06-18 Ciba-Geigy Corporation Certain -2-heterocycle substituted pyrazoloquinolines
JPS61112075A (en) * 1984-11-05 1986-05-30 Shionogi & Co Ltd Thienylpyrazoloquinoline derivative
SE8903564D0 (en) * 1989-10-26 1989-10-26 Pharmacia Ab NEW USE CONDENSED QUINOLINE COMPOUND
JPH05194515A (en) * 1991-07-31 1993-08-03 Kyowa Hakko Kogyo Co Ltd Condensed naphthyridine derivative

Also Published As

Publication number Publication date
AU712141B2 (en) 1999-10-28
BR9708103A (en) 1999-07-27
EP0888347A1 (en) 1999-01-07
TR199801861T2 (en) 1998-12-21
CA2247814A1 (en) 1997-09-25
SK118798A3 (en) 1999-03-12
CN1218472A (en) 1999-06-02
KR20000064716A (en) 2000-11-06
WO1997034893A1 (en) 1997-09-25
NO984290L (en) 1998-10-27
PL328921A1 (en) 1999-03-01
IS4848A (en) 1998-09-16
ID16283A (en) 1997-09-18
CZ297798A3 (en) 1999-03-17
IL126271A0 (en) 1999-05-09
EE9800298A (en) 1999-02-15
AR006520A1 (en) 1999-09-08
NO984290D0 (en) 1998-09-16
AU2186797A (en) 1997-10-10
JP2000506884A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
NZ331614A (en) 2-arylpyrazolisoquinoline and cinnolinone derivatives to treat asthma and/or rhinitis
ATE250576T1 (en) SUBSTITUTED PYRROLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION
PT907365E (en) NEW FORMULATION
GB0005251D0 (en) Therapeutic compounds
GB9406857D0 (en) Improvements in or relating to organic compounds
AU6998787A (en) Transglutaminase inhibitors
IL110943A0 (en) Compositions for the treatment of skin disorders
NZ332096A (en) Alpha-hydroxylic acid derivatives their production and use in treating conditions requiring endothelin inhibition
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
DE59813113D1 (en) Device for the cosmetic treatment of acne vulgaris
NO991619D0 (en) Use of an H +, K + -ATPase inhibitor in the treatment of nasal polyps
HK1048308A1 (en) Novel compounds.
NO984245D0 (en) Nasal administration of agents for the treatment of late onset emesis
DE59709081D1 (en) Use of bradykinin antagonists for the manufacture of medicaments for the treatment and prevention of Alzheimer's disease
FI971891A0 (en) Control device to achieve optimum use of the energy produced by the ship's main energy source
ATE491457T1 (en) COMBINATION THERAPY AGAINST TUMORS WITH SUBSTITUTED ACRYLOYL-DISTAMYCIN DERIVATIVES, TAXANS AND/OR ANTIMETABOLITES
NO974551D0 (en) Use of sulbutiamine to provide pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
DE59504374D1 (en) Use of deoxyspergualin for the manufacture of a medicament for the treatment of inflammatory hyperreactive diseases
HU9402283D0 (en) Aryl-alkoxy-phenoxy-imidazoline compounds
MD980248A (en) Carboline derivatives
NO954115L (en) Use of ceruletide-diethylamine salt in the treatment of psoriasis
ATE184487T1 (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR SILATRAN COMPOUNDS
MY120772A (en) Substituted benzopyran derivatives for the treatment of inflammation
UA40497A (en) METHOD OF TREATMENT OF GENERALIZED CATARRAL GINGIVITIS